Avalo Therapeutics (AVTX) Depreciation & Amortization (CF) (2014 - 2026)
Avalo Therapeutics (AVTX) posted Depreciation & Amortization (CF) of $17000.0 for Q1 2026, up 6.25% on a QoQ basis from $16000.0 in Q4 2025, and down 87.41% year-over-year from $135000.0 in Q1 2025.
Avalo Therapeutics (AVTX) Depreciation & Amortization (CF) (2014 - 2026) Analysis & Trends
Avalo Therapeutics' Depreciation & Amortization (CF) history runs 13 years deep, the most recent figure standing at $17000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 87.41% year-over-year to $17000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $226000.0 (down 16.3% YoY) and the FY2025 annual result came in at $344000.0, up 103.55% from the prior year.
- Depreciation & Amortization (CF) was $17000.0 for Q1 2026 at Avalo Therapeutics, up from $16000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $135000.0 in Q1 2025 and bottomed at $16000.0 in Q4 2025.
- A 5-year average of $50235.3 and a median of $35000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) plunged 93.42% — and 2025, when it jumped 306.06%.
- Avalo Therapeutics' Depreciation & Amortization (CF) stood at $35000.0 in 2022, then grew by 22.86% to $43000.0 in 2023, then jumped by 58.14% to $68000.0 in 2024, then slumped by 76.47% to $16000.0 in 2025, then grew by 6.25% to $17000.0 in 2026.
- Business Quant data shows AVTX's Depreciation & Amortization (CF) at $17000.0 in Q1 2026, $16000.0 in Q4 2025, and $59000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - | 17,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17,000.00 |
| Mar 31, 2026 | 17,000.00 |
| Dec 31, 2025 | 16,000.00 |
| Dec 31, 2025 | 16,000.00 |
| Sep 30, 2025 | 59,000.00 |
| Sep 30, 2025 | 59,000.00 |
| Jun 30, 2025 | 134,000.00 |
| Jun 30, 2025 | 134,000.00 |
| Mar 31, 2025 | 135,000.00 |
| Mar 31, 2025 | 135,000.00 |
| Dec 31, 2024 | 68,000.00 |
| Dec 31, 2024 | 68,000.00 |
| Sep 30, 2024 | 34,000.00 |
| Sep 30, 2024 | 34,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Jun 30, 2024 | 33,000.00 |
| Mar 31, 2024 | 34,000.00 |
| Mar 31, 2024 | 34,000.00 |
| Dec 31, 2023 | 43,000.00 |
| Dec 31, 2023 | 43,000.00 |